logo

iStock Rating

F
Details...
Enter Symbol click to research

Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX)

Sector: Medical

Current Price : $8.02

52 Week Low
$1.2852 Week High
$9.08
 

KERYX BIOP(NSDQ:KERX)
Keryx Biophamaceutical, Inc. uses data discovered through the mapping of the human genome to generate drug candidates that target the regulation of protein kinases. Protein kinases play a key role in the way cells communicate.
# Employees: 25
Address: 750 LEXINGTON AVENUE,NEW YORK,NY,USA
Phone: 212-531-5965
Fax: 212-531-5961
Website: www.keryx.com
Email: IR@keryx.com
Sector: Medical
Industry: MED-BIOMED/GENE
Executive Officers
Michael P. Tarnok (Chairman of the Board of Directors)
Ron Bentsur (Chief Executive Officer and Director)
James F. Oliviero (Chief Financial Officer)
Kevin Cameron (Director)
Joseph Feczko (Director,)
Dividend
Ex-Dividend Date: N/A
Annual Dividend: N/A
Current Dividend Yield: N/A
Dividend Paid (3 months): N/A
Indicated Dividend: N/A
Earnings
Last Earnings Date: 12/31/2012
Next Earnings Date(Expected): 5/7/2013
Mean EPS (Next Qtr): ($0.07)
Mean EPS (Year): ($0.25)
Mean Estimate(Long Term): ($0.01)
P/E Ratio(Based on EPS estimate): -0.010
Number of Estimates: 5
Shares Performance
Period kerx Compare to S&P
YTD 206.49 % 181.05 %
4 Weeks 13.58 % 13.70 %
12 Weeks 134.11 % 126.24 %
Shares Information
Analyst Coverage: Y
Avg Volume: 2245392
Shares Outstanding: 81M
Market Cap: $0.66B
52 Week High: $9.08
52 Week Low: $1.28
P/E Ratio: -0.010
PEG Ratio: -0.010
Split: On 1/1/1990 kerx split by factor of 0.010
Earnings Performance
EPS Growth in Last Quarter: -12.50 %
EPS Growth in Last Year: 25.00 %
Sales Growth in Last Quarter: -0.01 %
Sales Growth in Last Quarter: -0.01 %
Financials
Qtr Book Value: $55.06
Cash Flow/Share: ($0.01)
Change in Payout Ratio: -0.010
Price/Sales: -0.010
Home | Login |Research | Earnings | Scans | Charts | Submit Article | Join Blog Network | Advertise | Subscribe to RSS

Terms of Use | Privacy Policy | Copyright 2012 all rights reserved
Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia. Advertisement partners Investing Channel
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.